Research & Development
Qiagen, DiaSorin Widen Access to Latent TB Testing in the US with FDA Approval of QuantiFERON-TB Gold Plus assay on Liaison XS
1 December 2021 - - The US Food and Drug Administration has approved the Liaison QuantiFERON-TB Gold Plus assay for use on DiaSorin's automated Liaison XS platform, German sample and assay technologies provider Qiagen (NYSE: QGEN) (Frankfurt Prime Standard: QIA) and Italy-based in vitro eiagnostic specialist DiaSorin (FTSE MIB: DIA) said.

The approval widens the accessibility of US customers to automation solutions for processing Qiagen's leading blood-based test for latent tuberculosis detection and support the conversion from the traditional tuberculin skin tests that were developed over a century ago.

The highly automated workflow on Liaison platforms gives QuantiFERON customers a powerful, flexible automated option for all throughput ranges.

The addition of the fully automated Liaison XS platform to the already approved use of this assay on the Liaison XL version expands the range of potential customers to include experts at smaller healthcare clinics alongside those at larger hospitals and medical centers and reference laboratories.

Liaison QuantiFERON-TB Gold Plus is an interferon-gamma release assay developed by Qiagen and DiaSorin to offer streamlined laboratory automation for latent TB screening.

QuantiFERON-TB which tests for interferon-gamma released from T-cells that have encountered TB bacteria has been available on Liaison XL platforms in the US since 2019.

Qiagen and DiaSorin will continue to cooperate closely on the promotion and sale of their joint solutions for TB testing to make sure their customers reap the full benefit of their collaboration.

Qiagen is a provider of Sample to Insight solutions that enable customers to gain molecular insights from samples containing the building blocks of life.

Its sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials.

Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows.

As of September 30, 2021, Qiagen employed approximately 6,000 people in over 35 locations worldwide.

Headquartered in Italy DiaSorin is in the in vitro eiagnostic field and is active since 2021 in the life science business.

For over 50 years, the company has been developing, producing and marketing reagent kits used by diagnostic laboratories worldwide.